US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Acrivon Therapeutics, Inc.

1.67

+0.07004.37%

Post-market: 1.670.00000.00%19:48 EST

Volume:619.83K

Turnover:1.03M

Market Cap:52.70M

PE:-0.78

High:1.71

Open:1.61

Low:1.61

Close:1.60

52wk High:6.59

52wk Low:1.05

Shares:31.56M

Float Shares:16.70M

Volume Ratio:1.01

T/O Rate:3.71%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-2.1282

EPS(LYR):-2.3839

ROE:-50.23%

ROA:-30.89%

PB:0.41

PE(LYR):-0.70

Loading ...

Overview Company News Filings

Acrivon Therapeutics Announces Late-Breaking Oral Presentation at Upcoming European Society of Gynecological Oncology (Esgo) Annual International Congress

THOMSON REUTERS

Insider Spends US$82k Buying More Shares In Acrivon Therapeutics

Simply Wall St.

Acrivon Therapeutics CEO Peter Blume-Jensen Reports Acquisition of Common Shares

Acrivon COO Eric Devroe Acquires Common Shares

Acrivon Therapeutics Unveils Clinical Data and Pipeline Updates for ACR-368 and ACR-2316

Focused Clinical Strategy and Accelerated Approval Path for ACR-368 in High-Need Serous Endometrial Cancer Underpin ACRV Buy Rating

Acrivon Therapeutics Reports Over 50% Response Rate in Phase 2b Endometrial Cancer Trial

Acrivon Therapeutics Announces Positive Acr-368 Phase 2B Endometrial Cancer Clinical Data With EU Expansion to Accelerate Enrollment, Initial Acr-2316 Clinical Data, and Acr-6840, Its Next AP3-Enabled Development Candidate, Targeting Cdk11

THOMSON REUTERS

Acrivon Therapeutics Inc - Acr-2316 Phase 1 Shows Favorable Tolerability

THOMSON REUTERS

Acrivon Therapeutics Announces Clinical Updates for ACR-368 and ACR-2316 in Ongoing Trials

BRIEF-Acrivon Therapeutics To Announce Clinical Update

Acrivon Therapeutics Announces Upcoming Clinical Data Updates for ACR-368 and ACR-2316 Trials

Acrivon Therapeutics Showcases Advances in Precision Proteomics and Next-Generation Medicine in New Corporate Presentation

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Intellia Therapeutics (NTLA) and Acrivon Therapeutics, Inc. (ACRV)

Analysts’ Top Healthcare Picks: Acrivon Therapeutics, Inc. (ACRV), Sera Prognostics (SERA)

Acrivon Therapeutics Q3 net loss narrows to $18.2 mln

Acrivon Therapeutics, Inc Q3 Income From Operations USD -19.687 Million

Calendar of U.S. Earnings Expected in the Week Ahead

Acrivon Therapeutics Announces Initial Clinical Data for Novel WEE1/PKMYT1 Inhibitor ACR-2316

Acrivon Therapeutics Grants Stock Options to New Employee Under 2023 Inducement Plan

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/ACRV/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ACRV","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ACRV\",,,,,undefined,":{"symbol":"ACRV","market":"US","secType":"STK","nameCN":"Acrivon Therapeutics, Inc.","latestPrice":1.67,"timestamp":1770411600000,"preClose":1.6,"halted":0,"volume":619827,"hourTrading":{"tag":"盘后","latestPrice":1.67,"preClose":1.67,"latestTime":"19:48 EST","volume":3345,"amount":5615.5286,"timestamp":1770425285369,"change":0,"changeRate":0,"amplitude":0.035928},"delay":0,"changeRate":0.0437499999999999,"floatShares":16704630,"shares":31555126,"eps":-2.128243,"marketStatus":"Market Closed","change":0.07,"latestTime":"02-06 16:00:00 EST","open":1.61,"high":1.71,"low":1.61,"amount":1032586.7205771001,"amplitude":0.0625,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.128243,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1770627600000},"marketStatusCode":7,"adr":0,"listingDate":1668488400000,"exchange":"NASDAQ","adjPreClose":1.6,"preHourTrading":{"tag":"盘前","latestPrice":1.62,"preClose":1.6,"latestTime":"09:28 EST","volume":2441,"amount":3917.2748148,"timestamp":1770388085055,"change":0.02,"changeRate":0.0125,"amplitude":0.05625},"postHourTrading":{"tag":"盘后","latestPrice":1.67,"preClose":1.67,"latestTime":"19:48 EST","volume":3345,"amount":5615.5286,"timestamp":1770425285369,"change":0,"changeRate":0,"amplitude":0.035928},"volumeRatio":1.010998822409335},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ACRV\",,,,,undefined,":{"symbol":"ACRV","floatShares":16704630,"roa":"-30.89%","roe":"-50.23%","lyrEps":-2.38389,"volumeRatio":1.010998822409335,"shares":31555126,"dividePrice":0,"high":1.71,"amplitude":0.0625,"preClose":1.6,"low":1.61,"week52Low":1.05,"pbRate":"0.41","week52High":6.59,"institutionHeld":0,"latestPrice":1.67,"eps":-2.128243,"divideRate":0,"volume":619827,"delay":0,"ttmEps":-2.128243,"open":1.61,"prevYearClose":2.41,"prevWeekClose":1.79,"prevMonthClose":1.79,"prevQuarterClose":2.41,"fiveDayClose":1.79,"twentyDayClose":1.93,"sixtyDayClose":2.03},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ACRV\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-11-13","symbol":"ACRV","fiscalQuarterEnding":"2025/09","expectedEps":-0.57,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1763010000000,"reportTimeType":"post","actualEps":-0.47},{"market":"US","date":"2025-08-13","symbol":"ACRV","fiscalQuarterEnding":"2025/06","expectedEps":-0.57,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1755057600000,"reportTimeType":"post","actualEps":-0.55},{"market":"US","date":"2025-05-14","symbol":"ACRV","fiscalQuarterEnding":"2025/03","expectedEps":-0.57,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1747195200000,"reportTimeType":"post","actualEps":-0.51},{"market":"US","date":"2025-03-27","symbol":"ACRV","fiscalQuarterEnding":"2024/12","expectedEps":-0.69,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1743048000000,"reportTimeType":"post","actualEps":-0.6}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ACRV\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ACRV\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.2222,"buy":0.6667,"hold":0.1111,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6667,"analysts":9,"updateTime":1747371600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ACRV\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ACRV","date":"2026-02-05","current":-0.784685,"percent":0.851572,"low":-18.228389,"twenty":-7.312046,"median":-2.790745,"eighty":-0.746522,"high":-0.393112,"avg":-4.150548,"sd":4.048516,"marketCap":53328162},"quantilePoints":[{"date":"2022-11-11","current":-11.86111,"twenty":-16.13111,"median":-16.13111,"eighty":-13.56911,"marketCap":235122787},{"date":"2022-11-18","current":-16.605358,"twenty":-17.148347,"median":-16.336664,"eighty":-13.56911,"marketCap":329168006},{"date":"2022-11-25","current":-13.1538,"twenty":-16.59273,"median":-14.65824,"eighty":-13.1538,"marketCap":260747787},{"date":"2022-12-02","current":-13.311646,"twenty":-16.459997,"median":-13.18537,"eighty":-13.1538,"marketCap":263876760},{"date":"2022-12-09","current":-13.1538,"twenty":-16.13111,"median":-13.18537,"eighty":-13.1538,"marketCap":260747787},{"date":"2022-12-16","current":-9.42062,"twenty":-15.609309,"median":-13.164324,"eighty":-13.1538,"marketCap":250409495},{"date":"2022-12-23","current":-9.15348,"twenty":-13.492642,"median":-13.1538,"eighty":-9.908718,"marketCap":243308642},{"date":"2022-12-30","current":-9.051338,"twenty":-13.374784,"median":-13.1538,"eighty":-9.15348,"marketCap":240593610},{"date":"2023-01-06","current":-9.114194,"twenty":-13.324274,"median":-13.1538,"eighty":-9.10948,"marketCap":242264399},{"date":"2023-01-13","current":-9.758474,"twenty":-13.286391,"median":-13.1538,"eighty":-9.096909,"marketCap":259389986},{"date":"2023-01-20","current":-11.102032,"twenty":-13.261136,"median":-11.86111,"eighty":-9.107908,"marketCap":295103100},{"date":"2023-01-27","current":-11.416314,"twenty":-13.210625,"median":-11.432028,"eighty":-9.118908,"marketCap":303457044},{"date":"2023-02-03","current":-14.967707,"twenty":-13.261136,"median":-11.549884,"eighty":-9.140908,"marketCap":397856621},{"date":"2023-02-10","current":-17.254113,"twenty":-13.707494,"median":-12.294777,"eighty":-9.280764,"marketCap":458631569},{"date":"2023-02-17","current":-16.963401,"twenty":-16.209458,"median":-13.1538,"eighty":-9.39862,"marketCap":450904170},{"date":"2023-02-24","current":-12.044879,"twenty":-16.13111,"median":-12.885585,"eighty":-9.423763,"marketCap":320164934},{"date":"2023-03-03","current":-16.499835,"twenty":-16.177918,"median":-13.1538,"eighty":-9.434763,"marketCap":438582102},{"date":"2023-03-10","current":-15.745556,"twenty":-16.430693,"median":-13.1538,"eighty":-9.447334,"marketCap":418532634},{"date":"2023-03-17","current":-15.714128,"twenty":-16.525265,"median":-13.1538,"eighty":-9.527476,"marketCap":417697240},{"date":"2023-03-24","current":-10.229897,"twenty":-16.430693,"median":-13.1538,"eighty":-9.461476,"marketCap":271920903},{"date":"2023-03-31","current":-8.928026,"twenty":-16.282979,"median":-13.1538,"eighty":-9.434763,"marketCap":278259784},{"date":"2023-04-06","current":-7.274688,"twenty":-16.215409,"median":-13.019693,"eighty":-9.37662,"marketCap":226730194},{"date":"2023-04-14","current":-6.723819,"twenty":-16.19352,"median":-12.044879,"eighty":-9.115765,"marketCap":209561261},{"date":"2023-04-21","current":-8.060143,"twenty":-16.13111,"median":-11.86111,"eighty":-9.056052,"marketCap":251210465},{"date":"2023-04-28","current":-8.650938,"twenty":-16.126284,"median":-11.549884,"eighty":-9.035624,"marketCap":269623798},{"date":"2023-05-05","current":-7.956584,"twenty":-16.088124,"median":-11.377028,"eighty":-8.91982,"marketCap":247982856},{"date":"2023-05-12","current":-8.118522,"twenty":-16.003268,"median":-11.21203,"eighty":-8.835959,"marketCap":297974095},{"date":"2023-05-19","current":-7.88554,"twenty":-15.962411,"median":-10.807392,"eighty":-8.673871,"marketCap":289422962},{"date":"2023-05-26","current":-7.467367,"twenty":-15.908983,"median":-10.229897,"eighty":-8.438641,"marketCap":274074775},{"date":"2023-06-02","current":-7.419576,"twenty":-15.745556,"median":-9.829187,"eighty":-8.257075,"marketCap":272320696},{"date":"2023-06-09","current":-7.353863,"twenty":-15.714128,"median":-9.671273,"eighty":-8.064756,"marketCap":269908838},{"date":"2023-06-16","current":-7.138803,"twenty":-14.967707,"median":-9.475619,"eighty":-7.88554,"marketCap":262015484},{"date":"2023-06-23","current":-7.694375,"twenty":-14.936279,"median":-9.444191,"eighty":-7.691985,"marketCap":282406648},{"date":"2023-06-30","current":-7.957226,"twenty":-14.607853,"median":-9.4246,"eighty":-7.737387,"marketCap":292054080},{"date":"2023-07-07","current":-6.962573,"twenty":-14.230714,"median":-9.36562,"eighty":-7.687206,"marketCap":255547320},{"date":"2023-07-14","current":-7.312046,"twenty":-13.800187,"median":-9.122051,"eighty":-7.479315,"marketCap":268374019},{"date":"2023-07-21","current":-7.795931,"twenty":-13.463178,"median":-9.09848,"eighty":-7.467367,"marketCap":286134065},{"date":"2023-07-28","current":-7.335941,"twenty":-13.349529,"median":-9.063123,"eighty":-7.467367,"marketCap":269251058},{"date":"2023-08-04","current":-7.049195,"twenty":-13.305332,"median":-9.04741,"eighty":-7.451835,"marketCap":258726587},{"date":"2023-08-11","current":-6.929717,"twenty":-13.273763,"median":-9.035624,"eighty":-7.414797,"marketCap":254341391},{"date":"2023-08-18","current":-5.439761,"twenty":-13.23588,"median":-8.933664,"eighty":-7.374175,"marketCap":243684992},{"date":"2023-08-25","current":-5.824092,"twenty":-13.18537,"median":-8.917768,"eighty":-7.335941,"marketCap":260901867},{"date":"2023-09-01","current":-5.774819,"twenty":-13.181161,"median":-8.846512,"eighty":-7.295319,"marketCap":258694575},{"date":"2023-09-08","current":-5.764965,"twenty":-13.164324,"median":-8.810263,"eighty":-7.252307,"marketCap":258253117},{"date":"2023-09-15","current":-5.415125,"twenty":-13.164324,"median":-8.657972,"eighty":-7.138803,"marketCap":242581346},{"date":"2023-09-22","current":-4.666172,"twenty":-13.15801,"median":-8.650938,"eighty":-7.070701,"marketCap":209030514},{"date":"2023-09-28","current":-4.848483,"twenty":-13.1538,"median":-8.470778,"eighty":-7.024104,"marketCap":217197493},{"date":"2023-10-06","current":-3.606798,"twenty":-13.1538,"median":-8.337045,"eighty":-6.962573,"marketCap":161573745},{"date":"2023-10-13","current":-3.074648,"twenty":-13.1538,"median":-8.233741,"eighty":-6.723819,"marketCap":137734995},{"date":"2023-10-20","current":-2.670607,"twenty":-13.1538,"median":-8.118522,"eighty":-6.217422,"marketCap":119635204},{"date":"2023-10-27","current":-2.498151,"twenty":-13.1538,"median":-8.106574,"eighty":-6.135872,"marketCap":111909684},{"date":"2023-11-03","current":-2.650898,"twenty":-13.1538,"median":-8.060143,"eighty":-5.913769,"marketCap":118752288},{"date":"2023-11-10","current":-2.023663,"twenty":-13.1538,"median":-7.990082,"eighty":-5.83986,"marketCap":101314684},{"date":"2023-11-17","current":-1.968296,"twenty":-13.1538,"median":-7.956584,"eighty":-5.774819,"marketCap":98542723},{"date":"2023-11-24","current":-1.70231,"twenty":-13.1538,"median":-7.867618,"eighty":-5.710764,"marketCap":85226138},{"date":"2023-12-01","current":-1.795405,"twenty":-12.885585,"median":-7.837749,"eighty":-5.538308,"marketCap":89886943},{"date":"2023-12-08","current":-2.38944,"twenty":-12.728444,"median":-7.795931,"eighty":-5.434834,"marketCap":119627314},{"date":"2023-12-15","current":-2.220982,"twenty":-12.181592,"median":-7.694375,"eighty":-5.139195,"marketCap":111193478},{"date":"2023-12-22","current":-2.158919,"twenty":-11.988308,"median":-7.676453,"eighty":-4.765704,"marketCap":108086275},{"date":"2023-12-29","current":-2.207683,"twenty":-11.903452,"median":-7.658532,"eighty":-4.607044,"marketCap":110527648},{"date":"2024-01-05","current":-2.061391,"twenty":-11.878047,"median":-7.57191,"eighty":-4.424734,"marketCap":103203527},{"date":"2024-01-12","current":-2.136753,"twenty":-11.86111,"median":-7.467367,"eighty":-3.380635,"marketCap":106976559},{"date":"2024-01-19","current":-1.928398,"twenty":-11.771191,"median":-7.467367,"eighty":-3.021433,"marketCap":96545235},{"date":"2024-01-26","current":-1.795405,"twenty":-11.601741,"median":-7.461393,"eighty":-2.812514,"marketCap":89886943},{"date":"2024-02-02","current":-1.711176,"twenty":-11.509027,"median":-7.449445,"eighty":-2.678491,"marketCap":85670025},{"date":"2024-02-09","current":-1.569317,"twenty":-11.435171,"median":-7.416589,"eighty":-2.525448,"marketCap":78567846},{"date":"2024-02-16","current":-1.773239,"twenty":-11.384886,"median":-7.389706,"eighty":-2.417812,"marketCap":88777228},{"date":"2024-02-23","current":-1.693444,"twenty":-11.315743,"median":-7.371785,"eighty":-2.305211,"marketCap":84782252},{"date":"2024-03-01","current":-2.154486,"twenty":-11.224602,"median":-7.341915,"eighty":-2.222755,"marketCap":107864332},{"date":"2024-03-08","current":-2.274179,"twenty":-11.19003,"median":-7.329968,"eighty":-2.220982,"marketCap":113856794},{"date":"2024-03-15","current":-2.247581,"twenty":-11.059604,"median":-7.297111,"eighty":-2.213003,"marketCap":112525136},{"date":"2024-03-22","current":-2.806151,"twenty":-10.856891,"median":-7.272415,"eighty":-2.217436,"marketCap":140489963},{"date":"2024-03-28","current":-2.376071,"twenty":-10.724892,"median":-7.222437,"eighty":-2.220982,"marketCap":143486194},{"date":"2024-04-05","current":-2.507803,"twenty":-10.284897,"median":-7.147764,"eighty":-2.220982,"marketCap":151441202},{"date":"2024-04-12","current":-3.482435,"twenty":-10.229897,"median":-7.085038,"eighty":-2.220982,"marketCap":210297274},{"date":"2024-04-19","current":-5.388706,"twenty":-10.049185,"median":-7.03426,"eighty":-2.229848,"marketCap":325413151},{"date":"2024-04-26","current":-4.330392,"twenty":-9.829187,"median":-6.98405,"eighty":-2.238715,"marketCap":261503737},{"date":"2024-05-03","current":-4.325468,"twenty":-9.758474,"median":-6.941664,"eighty":-2.247581,"marketCap":261206357},{"date":"2024-05-10","current":-4.161857,"twenty":-9.701929,"median":-6.723819,"eighty":-2.252014,"marketCap":251326211},{"date":"2024-05-17","current":-4.122189,"twenty":-9.640618,"median":-6.484687,"eighty":-2.274179,"marketCap":264306537},{"date":"2024-05-24","current":-3.905485,"twenty":-9.530619,"median":-6.182256,"eighty":-2.300778,"marketCap":250411918},{"date":"2024-05-31","current":-3.717675,"twenty":-9.486619,"median":-5.962057,"eighty":-2.304324,"marketCap":238369915},{"date":"2024-06-07","current":-3.49134,"twenty":-9.456762,"median":-5.903338,"eighty":-2.319397,"marketCap":223857757},{"date":"2024-06-14","current":-3.49134,"twenty":-9.445762,"median":-5.863511,"eighty":-2.33713,"marketCap":223857757},{"date":"2024-06-21","current":-3.183139,"twenty":-9.434763,"median":-5.824092,"eighty":-2.361913,"marketCap":204096520},{"date":"2024-06-28","current":-2.793072,"twenty":-9.426151,"median":-5.774819,"eighty":-2.384092,"marketCap":179086205},{"date":"2024-07-05","current":-3.404659,"twenty":-9.423008,"median":-5.767428,"eighty":-2.38944,"marketCap":218299909},{"date":"2024-07-12","current":-3.587653,"twenty":-9.39862,"median":-5.666418,"eighty":-2.403626,"marketCap":230033143},{"date":"2024-07-19","current":-3.529865,"twenty":-9.280764,"median":-5.543235,"eighty":-2.426576,"marketCap":226327911},{"date":"2024-07-26","current":-4.266659,"twenty":-9.140908,"median":-5.474253,"eighty":-2.441598,"marketCap":273569617},{"date":"2024-08-02","current":-3.63581,"twenty":-9.122051,"median":-5.42498,"eighty":-2.474845,"marketCap":233120836},{"date":"2024-08-09","current":-3.703229,"twenty":-9.118908,"median":-5.388706,"eighty":-2.497195,"marketCap":237443607},{"date":"2024-08-16","current":-3.411328,"twenty":-9.107908,"median":-5.155584,"eighty":-2.500122,"marketCap":235388438},{"date":"2024-08-23","current":-4.201319,"twenty":-9.095337,"median":-5.020597,"eighty":-2.503539,"marketCap":289899445},{"date":"2024-08-30","current":-4.259671,"twenty":-9.084337,"median":-4.902952,"eighty":-2.504417,"marketCap":293925826},{"date":"2024-09-06","current":-3.62678,"twenty":-9.070195,"median":-4.859549,"eighty":-2.505321,"marketCap":250255077},{"date":"2024-09-13","current":-3.999333,"twenty":-9.051338,"median":-4.841316,"eighty":-2.507803,"marketCap":275961972},{"date":"2024-09-20","current":-3.352976,"twenty":-9.049767,"median":-4.688345,"eighty":-2.511616,"marketCap":231362057},{"date":"2024-09-27","current":-3.21383,"twenty":-9.04191,"median":-4.607044,"eighty":-2.532949,"marketCap":221760687},{"date":"2024-10-04","current":-3.146501,"twenty":-9.035624,"median":-4.498696,"eighty":-2.562206,"marketCap":217114862},{"date":"2024-10-11","current":-3.272182,"twenty":-9.016796,"median":-4.434588,"eighty":-2.595712,"marketCap":225787068},{"date":"2024-10-18","current":-3.703086,"twenty":-8.941048,"median":-4.32793,"eighty":-2.65484,"marketCap":255520344},{"date":"2024-10-25","current":-3.572917,"twenty":-8.937048,"median":-4.281106,"eighty":-2.672533,"marketCap":246538417},{"date":"2024-11-01","current":-3.59536,"twenty":-8.928026,"median":-4.264137,"eighty":-2.682254,"marketCap":248087025},{"date":"2024-11-08","current":-3.846721,"twenty":-8.925974,"median":-4.246205,"eighty":-2.692288,"marketCap":265431436},{"date":"2024-11-15","current":-2.815239,"twenty":-8.917768,"median":-4.204595,"eighty":-2.703682,"marketCap":216708620},{"date":"2024-11-22","current":-2.649398,"twenty":-8.907034,"median":-4.16553,"eighty":-2.65484,"marketCap":203942738},{"date":"2024-11-29","current":-3.066021,"twenty":-8.864099,"median":-4.160922,"eighty":-2.670607,"marketCap":236013123},{"date":"2024-12-06","current":-2.596815,"twenty":-8.828924,"median":-4.126009,"eighty":-2.650898,"marketCap":199895020},{"date":"2024-12-13","current":-2.855687,"twenty":-8.814854,"median":-4.120525,"eighty":-2.670607,"marketCap":219822249},{"date":"2024-12-20","current":-2.714117,"twenty":-8.805671,"median":-4.068333,"eighty":-2.680238,"marketCap":208924546},{"date":"2024-12-27","current":-2.394571,"twenty":-8.751109,"median":-4.0331,"eighty":-2.645353,"marketCap":184326872},{"date":"2025-01-03","current":-2.677713,"twenty":-8.689771,"median":-4.012605,"eighty":-2.604905,"marketCap":206122279},{"date":"2025-01-10","current":-2.212551,"twenty":-8.655158,"median":-3.960865,"eighty":-2.587876,"marketCap":170315539},{"date":"2025-01-17","current":-2.337942,"twenty":-8.650938,"median":-3.900584,"eighty":-2.551877,"marketCap":179967790},{"date":"2025-01-24","current":-2.204461,"twenty":-8.625618,"median":-3.852513,"eighty":-2.521343,"marketCap":169692813},{"date":"2025-01-31","current":-2.455244,"twenty":-8.502914,"median":-3.835171,"eighty":-2.504323,"marketCap":188997316},{"date":"2025-02-07","current":-2.43502,"twenty":-8.401182,"median":-3.809173,"eighty":-2.50322,"marketCap":187440501},{"date":"2025-02-14","current":-2.192327,"twenty":-8.329184,"median":-3.763471,"eighty":-2.461772,"marketCap":168758724},{"date":"2025-02-21","current":-2.240865,"twenty":-8.297738,"median":-3.75246,"eighty":-2.43502,"marketCap":172495079},{"date":"2025-02-28","current":-2.147833,"twenty":-8.257075,"median":-3.717675,"eighty":-2.390526,"marketCap":165333731},{"date":"2025-03-07","current":-2.240865,"twenty":-8.210407,"median":-3.714869,"eighty":-2.366257,"marketCap":172495079},{"date":"2025-03-14","current":-2.200416,"twenty":-8.154365,"median":-3.703229,"eighty":-2.322944,"marketCap":169381450},{"date":"2025-03-21","current":-2.168057,"twenty":-8.118522,"median":-3.698597,"eighty":-2.300778,"marketCap":166890546},{"date":"2025-03-28","current":-0.871783,"twenty":-8.106574,"median":-3.680643,"eighty":-2.269179,"marketCap":70227315},{"date":"2025-04-04","current":-0.587675,"twenty":-8.064756,"median":-3.655072,"eighty":-2.252014,"marketCap":47340734},{"date":"2025-04-11","current":-0.630486,"twenty":-8.060143,"median":-3.640625,"eighty":-2.24491,"marketCap":50789397},{"date":"2025-04-17","current":-0.704431,"twenty":-8.039938,"median":-3.63581,"eighty":-2.240865,"marketCap":56746178},{"date":"2025-04-25","current":-0.638341,"twenty":-8.020549,"median":-3.631295,"eighty":-2.235426,"marketCap":51422173},{"date":"2025-05-02","current":-0.548817,"twenty":-7.973953,"median":-3.617803,"eighty":-2.223945,"marketCap":44210527},{"date":"2025-05-09","current":-0.451509,"twenty":-7.958421,"median":-3.612522,"eighty":-2.214841,"marketCap":36371781},{"date":"2025-05-16","current":-0.430551,"twenty":-7.956712,"median":-3.606138,"eighty":-2.211394,"marketCap":36058665},{"date":"2025-05-23","current":-0.430551,"twenty":-7.899749,"median":-3.596322,"eighty":-2.204461,"marketCap":36058665},{"date":"2025-05-30","current":-0.411832,"twenty":-7.874787,"median":-3.589262,"eighty":-2.194384,"marketCap":34490897},{"date":"2025-06-06","current":-0.46799,"twenty":-7.860449,"median":-3.572307,"eighty":-2.185046,"marketCap":39194201},{"date":"2025-06-13","current":-0.475478,"twenty":-7.85567,"median":-3.556351,"eighty":-2.168057,"marketCap":39821308},{"date":"2025-06-20","current":-0.464247,"twenty":-7.841333,"median":-3.540333,"eighty":-2.161322,"marketCap":38880647},{"date":"2025-06-27","current":-0.490454,"twenty":-7.815048,"median":-3.529865,"eighty":-2.150494,"marketCap":41075522},{"date":"2025-07-03","current":-0.482966,"twenty":-7.805489,"median":-3.520234,"eighty":-2.141361,"marketCap":40448415},{"date":"2025-07-11","current":-0.50543,"twenty":-7.789957,"median":-3.49134,"eighty":-2.109268,"marketCap":42329737},{"date":"2025-07-18","current":-0.494198,"twenty":-7.751725,"median":-3.478657,"eighty":-2.07907,"marketCap":41389076},{"date":"2025-07-25","current":-0.520405,"twenty":-7.691985,"median":-3.452815,"eighty":-2.037985,"marketCap":43583951},{"date":"2025-08-01","current":-0.479222,"twenty":-7.680037,"median":-3.411328,"eighty":-2.021493,"marketCap":40134862},{"date":"2025-08-08","current":-0.475478,"twenty":-7.66809,"median":-3.410401,"eighty":-1.970956,"marketCap":39821308},{"date":"2025-08-15","current":-0.508659,"twenty":-7.656142,"median":-3.404659,"eighty":-1.930615,"marketCap":43723346},{"date":"2025-08-22","current":-0.483043,"twenty":-7.616715,"median":-3.37891,"eighty":-1.884954,"marketCap":41521451},{"date":"2025-08-29","current":-0.486703,"twenty":-7.496042,"median":-3.352976,"eighty":-1.788312,"marketCap":41836007},{"date":"2025-09-05","current":-0.475725,"twenty":-7.491263,"median":-3.313162,"eighty":-1.768806,"marketCap":40892338},{"date":"2025-09-12","current":-0.56721,"twenty":-7.467367,"median":-3.258716,"eighty":-1.720042,"marketCap":48756249},{"date":"2025-09-19","current":-0.611123,"twenty":-7.467367,"median":-3.24525,"eighty":-1.70231,"marketCap":52530927},{"date":"2025-09-26","current":-0.563551,"twenty":-7.467367,"median":-3.222807,"eighty":-1.693444,"marketCap":48441693},{"date":"2025-10-03","current":-0.680652,"twenty":-7.467367,"median":-3.207592,"eighty":-1.640246,"marketCap":58507499},{"date":"2025-10-10","current":-0.717246,"twenty":-7.461393,"median":-3.192079,"eighty":-1.613648,"marketCap":61653064},{"date":"2025-10-17","current":-0.684312,"twenty":-7.461393,"median":-3.15099,"eighty":-1.551584,"marketCap":58822056},{"date":"2025-10-24","current":-0.731884,"twenty":-7.449445,"median":-3.142012,"eighty":-0.871783,"marketCap":62911290},{"date":"2025-10-31","current":-0.709928,"twenty":-7.449445,"median":-3.137524,"eighty":-0.778377,"marketCap":61023951},{"date":"2025-11-07","current":-0.731884,"twenty":-7.431524,"median":-3.124058,"eighty":-0.764819,"marketCap":62911290},{"date":"2025-11-14","current":-0.7575,"twenty":-7.419576,"median":-3.074648,"eighty":-0.7575,"marketCap":65113185},{"date":"2025-11-21","current":-0.872339,"twenty":-7.413602,"median":-3.028172,"eighty":-0.7575,"marketCap":71314584},{"date":"2025-11-28","current":-0.910938,"twenty":-7.394485,"median":-3.011416,"eighty":-0.7575,"marketCap":74470097},{"date":"2025-12-05","current":-0.930238,"twenty":-7.389706,"median":-2.985956,"eighty":-0.763355,"marketCap":76047853},{"date":"2025-12-12","current":-1.007436,"twenty":-7.384928,"median":-2.942357,"eighty":-0.772552,"marketCap":82358878},{"date":"2025-12-19","current":-0.872339,"twenty":-7.374175,"median":-2.916361,"eighty":-0.777599,"marketCap":71314584},{"date":"2025-12-26","current":-0.922518,"twenty":-7.361032,"median":-2.855687,"eighty":-0.783416,"marketCap":75416751},{"date":"2026-01-02","current":-0.930238,"twenty":-7.351473,"median":-2.838136,"eighty":-0.788086,"marketCap":76047853},{"date":"2026-01-09","current":-0.744962,"twenty":-7.34311,"median":-2.832314,"eighty":-0.788086,"marketCap":60901393},{"date":"2026-01-16","current":-0.721803,"twenty":-7.335941,"median":-2.819283,"eighty":-0.760428,"marketCap":59008085},{"date":"2026-01-23","current":-0.783561,"twenty":-7.334746,"median":-2.806151,"eighty":-0.758852,"marketCap":64056905},{"date":"2026-01-30","current":-0.725663,"twenty":-7.326384,"median":-2.795895,"eighty":-0.7575,"marketCap":59323636},{"date":"2026-02-05","current":-0.652324,"twenty":-7.312046,"median":-2.790745,"eighty":-0.746522,"marketCap":53328162}],"updateTime":1770430566541},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ACRV\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2605408868","title":"Acrivon Therapeutics Announces Late-Breaking Oral Presentation at Upcoming European Society of Gynecological Oncology (Esgo) Annual International Congress","url":"https://stock-news.laohu8.com/highlight/detail?id=2605408868","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605408868?lang=en_us&edition=fundamental","pubTime":"2026-01-23 21:11","pubTimestamp":1769173893,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260123:nTUA5RK7JN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ACRV"],"gpt_icon":0},{"id":"2604071976","title":"Insider Spends US$82k Buying More Shares In Acrivon Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2604071976","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604071976?lang=en_us&edition=fundamental","pubTime":"2026-01-18 21:24","pubTimestamp":1768742679,"startTime":"0","endTime":"0","summary":"Even if it's not a huge purchase, we think it was good to see that Peter Blume-Jensen, the Co-Founder of Acrivon...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-acrv/acrivon-therapeutics/news/insider-spends-us82k-buying-more-shares-in-acrivon-therapeut","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-acrv/acrivon-therapeutics/news/insider-spends-us82k-buying-more-shares-in-acrivon-therapeut","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ACRV","BK4139","BK4007","BK4539","LENZ"],"gpt_icon":0},{"id":"2604195479","title":"Acrivon Therapeutics CEO Peter Blume-Jensen Reports Acquisition of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2604195479","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604195479?lang=en_us&edition=fundamental","pubTime":"2026-01-17 05:03","pubTimestamp":1768597408,"startTime":"0","endTime":"0","summary":"Peter Blume-Jensen, President and CEO of Acrivon Therapeutics Inc., reported the acquisition of common shares of Acrivon Therapeutics Inc., according to a recent SEC filing. Other reporting beneficial owners include Kristina Masson, EVP - Business Operations, and other reporting beneficial owners. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Acrivon Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 16, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260116:nNDL1W5HPn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Acrivon Therapeutics CEO Peter Blume-Jensen Reports Acquisition of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ACRV"],"gpt_icon":0},{"id":"2603936395","title":"Acrivon COO Eric Devroe Acquires Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2603936395","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603936395?lang=en_us&edition=fundamental","pubTime":"2026-01-16 05:39","pubTimestamp":1768513146,"startTime":"0","endTime":"0","summary":"Eric Devroe, Chief Operating Officer of Acrivon Therapeutics Inc., reported the acquisition of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Acrivon Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 15, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260115:nNDL2fqWqS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Acrivon COO Eric Devroe Acquires Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACRV","BK4139"],"gpt_icon":0},{"id":"2602326275","title":"Acrivon Therapeutics Unveils Clinical Data and Pipeline Updates for ACR-368 and ACR-2316","url":"https://stock-news.laohu8.com/highlight/detail?id=2602326275","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602326275?lang=en_us&edition=fundamental","pubTime":"2026-01-09 17:14","pubTimestamp":1767950092,"startTime":"0","endTime":"0","summary":"Acrivon Therapeutics Inc. recently held a conference call to discuss clinical data and pipeline updates for its leading drug candidates, ACR-368 and ACR-2316. The presentation included initial Phase 1 clinical data for ACR-2316 and Phase 2b data for ACR-368, with updates on program progress and the nomination of a development candidate for the company’s cell cycle program. ACR-368, evaluated as a single agent in endometrial cancer subjects identified as OncoSignature-positive, demonstrated an objective response rate  of 39% in the analyzed cohort. The company's AI-driven AP3 platform, designed to match disease-driving pathways with drug mechanisms, was also highlighted as a key component of its approach to precision medicine. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for in","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260109:nNDL19znTz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACRV","BK4139"],"gpt_icon":0},{"id":"2602439177","title":"Focused Clinical Strategy and Accelerated Approval Path for ACR-368 in High-Need Serous Endometrial Cancer Underpin ACRV Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2602439177","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602439177?lang=en_us&edition=fundamental","pubTime":"2026-01-09 01:35","pubTimestamp":1767893734,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Emily Bodnar maintained a Buy rating on Acrivon Therapeutics, Inc. today and set a price target of $19.00. Emily Bodnar has...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/focused-clinical-strategy-and-accelerated-approval-path-for-acr-368-in-high-need-serous-endometrial-cancer-underpin-acrv-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/focused-clinical-strategy-and-accelerated-approval-path-for-acr-368-in-high-need-serous-endometrial-cancer-underpin-acrv-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ACRV","ACR"],"gpt_icon":0},{"id":"2601773369","title":"Acrivon Therapeutics Reports Over 50% Response Rate in Phase 2b Endometrial Cancer Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2601773369","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601773369?lang=en_us&edition=fundamental","pubTime":"2026-01-08 20:30","pubTimestamp":1767875436,"startTime":"0","endTime":"0","summary":"Acrivon Therapeutics Inc. announced significant progress in its clinical pipeline, including updates from the ongoing Phase 2b trial of ACR-368 in endometrial cancer. Interim electronic data capture from the study showed an overall response rate of 39% among OncoSignature-positive subjects, with a 44% response rate in those with two or fewer prior lines of therapy. In the subset of serous endometrial cancer patients with two or fewer prior treatments, a confirmed overall response rate of 52% was observed, and 67% in biomarker-positive subjects. The company also reported initial clinical data from the ACR-2316 Phase 1 study and announced the nomination of ACR-6840, a potential first-in-class oral CDK11 inhibitor, as its next preclinical development candidate. Results from the ACR-368 trial have already been presented, and the company has submitted a Phase 3 study protocol for ACR-368 in combination with anti-PD-1 therapy to the FDA.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nNDL8dR3GK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","LU2210150020.SGD","LU0314104364.USD","BK4585","BK4588","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","LU2095319765.USD","NDAQ","IE00BKPKM429.USD","SG9999014013.SGD","SG9999014039.USD","IE00B64PRP62.GBP","BK4139","ACRV","SG9999014005.SGD","LU2210149790.SGD","SG9999014021.USD"],"gpt_icon":0},{"id":"2601369089","title":"Acrivon Therapeutics Announces Positive Acr-368 Phase 2B Endometrial Cancer Clinical Data With EU Expansion to Accelerate Enrollment, Initial Acr-2316 Clinical Data, and Acr-6840, Its Next AP3-Enabled Development Candidate, Targeting Cdk11","url":"https://stock-news.laohu8.com/highlight/detail?id=2601369089","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601369089?lang=en_us&edition=fundamental","pubTime":"2026-01-08 20:30","pubTimestamp":1767875400,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nTUA6CQC6C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ACRV","BK4139"],"gpt_icon":0},{"id":"2601369042","title":"Acrivon Therapeutics Inc - Acr-2316 Phase 1 Shows Favorable Tolerability","url":"https://stock-news.laohu8.com/highlight/detail?id=2601369042","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601369042?lang=en_us&edition=fundamental","pubTime":"2026-01-08 20:30","pubTimestamp":1767875400,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nTUA6CQC6C:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ACRV","BK4139"],"gpt_icon":0},{"id":"2601559892","title":"Acrivon Therapeutics Announces Clinical Updates for ACR-368 and ACR-2316 in Ongoing Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2601559892","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601559892?lang=en_us&edition=fundamental","pubTime":"2026-01-06 20:30","pubTimestamp":1767702625,"startTime":"0","endTime":"0","summary":"Acrivon Therapeutics Inc. announced that it will provide updates on its ongoing clinical programs, including interim data from the registrational-intent Phase 2b study of ACR-368 in endometrial cancer and initial clinical data from the Phase 1 study of ACR-2316, a WEE1/PKMYT1 inhibitor. The company will also discuss the planned confirmatory Phase 3 trial for ACR-368 and the nomination of a new preclinical development candidate from its AP3-driven cell cycle program. These updates will be shared via a press release at 7:30 a.m. ET, followed by a conference call and webcast at 8:30 a.m. ET on Thursday, January 8, 2026. Results have not yet been presented and will be disclosed during the scheduled event.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or l","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260106:nNDL9QbHLp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014039.USD","IE00BKPKM429.USD","SG9999014021.USD","BK4112","IE00B64PRP62.GBP","LU2210149790.SGD","BK4139","LU0314104364.USD","SG9999014005.SGD","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","BK4585","ACRV","LU2210150020.SGD","NDAQ","SG9999014013.SGD","LU2095319765.USD","BK4588"],"gpt_icon":0},{"id":"2592918088","title":"BRIEF-Acrivon Therapeutics To Announce Clinical Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2592918088","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592918088?lang=en_us&edition=fundamental","pubTime":"2025-12-17 21:43","pubTimestamp":1765979033,"startTime":"0","endTime":"0","summary":"BRIEF-Acrivon Therapeutics To Announce Clinical Update Dec 17 (Reuters) - Acrivon Therapeutics Inc ACRV.O:ACRIVON THERAPEUTICS TO ANNOUNCE CLINICAL UPDATE ON ITS ONGOING PHASE 2B STUDIES AND PLANNED C","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nTUA34T5DX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ACRV"],"gpt_icon":0},{"id":"2592975509","title":"Acrivon Therapeutics Announces Upcoming Clinical Data Updates for ACR-368 and ACR-2316 Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2592975509","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592975509?lang=en_us&edition=fundamental","pubTime":"2025-12-17 20:30","pubTimestamp":1765974617,"startTime":"0","endTime":"0","summary":"Acrivon Therapeutics Inc. has announced that it will provide clinical updates in January 2026 on several ongoing studies and pipeline developments. The company will present updated interim clinical data from its ongoing registrational-intent Phase 2b study of ACR-368 , a selective CHK1/CHK2 inhibitor, in endometrial cancer, along with information on a recently initiated tumor biopsy-independent Phase 2b arm and the planned confirmatory Phase 3 trial. Initial clinical data from the ongoing Phase 1 study of ACR-2316, a WEE1/PKMYT1 inhibitor, will also be shared, including safety data, dosing regimen, and early clinical activity. Additionally, Acrivon will announce the nomination of a new preclinical development candidate for its AP3-driven cell cycle program. The results and updates will be presented in the future.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nNDL2c2BHr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","ACRV","SG9999014013.SGD","LU2210149790.SGD","BK4585","SG9999014039.USD","IE00BGHQF748.EUR","BK4112","IE00BKPKM429.USD","BK4139","SG9999014005.SGD","LU2210150020.SGD","IE00B3QW5Z07.USD","SG9999014021.USD","LU0314104364.USD","NDAQ","LU2095319765.USD","BK4588"],"gpt_icon":0},{"id":"2585712844","title":"Acrivon Therapeutics Showcases Advances in Precision Proteomics and Next-Generation Medicine in New Corporate Presentation","url":"https://stock-news.laohu8.com/highlight/detail?id=2585712844","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585712844?lang=en_us&edition=fundamental","pubTime":"2025-11-22 03:01","pubTimestamp":1763751704,"startTime":"0","endTime":"0","summary":"Acrivon Therapeutics Inc. has released a corporate presentation detailing its advancements in next-generation precision medicine. The presentation highlights the company's Acrivon Predictive Precision Proteomics  platform, which is designed to enable precise matching of disease-driving, dysregulated pathways with targeted therapies. The document outlines the company's research and development activities across its Boston and Lund/Copenhagen sites, including drug development, clinical biomarkers, mass spectrometry, and early pipeline drug discovery programs. Key leadership team members and their backgrounds are also presented. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Acr","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251121:nNDLbtGqMs:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACRV","BK4139"],"gpt_icon":0},{"id":"2583656346","title":"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Intellia Therapeutics (NTLA) and Acrivon Therapeutics, Inc. (ACRV)","url":"https://stock-news.laohu8.com/highlight/detail?id=2583656346","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583656346?lang=en_us&edition=fundamental","pubTime":"2025-11-16 00:50","pubTimestamp":1763225432,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Intellia Therapeutics (NTLA – Research Report) and...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-intellia-therapeutics-ntla-and-acrivon-therapeutics-inc-acrv-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-intellia-therapeutics-ntla-and-acrivon-therapeutics-inc-acrv-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","XLV","LU0128526141.USD","NTLA","HCSG","BK4588","BK4535","LU0029874061.USD","LU1861558580.USD","BK4556","XBI","BK4581","LU1861559042.SGD","BK4137","ACRV","LABU","BK4139"],"gpt_icon":0},{"id":"2583265045","title":"Analysts’ Top Healthcare Picks: Acrivon Therapeutics, Inc. (ACRV), Sera Prognostics (SERA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2583265045","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583265045?lang=en_us&edition=fundamental","pubTime":"2025-11-14 13:10","pubTimestamp":1763097019,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Acrivon Therapeutics, Inc. (ACRV – Research Report) ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-acrivon-therapeutics-inc-acrv-sera-prognostics-sera-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-acrivon-therapeutics-inc-acrv-sera-prognostics-sera-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0128526141.USD","BK4137","SERA","BK4581","LU0029874061.USD","BK4539","ACRV","BK4585","XLV","XBI","LABU","HCSG","BK4588","BK4139"],"gpt_icon":0},{"id":"2583512977","title":"Acrivon Therapeutics Q3 net loss narrows to $18.2 mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2583512977","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583512977?lang=en_us&edition=fundamental","pubTime":"2025-11-14 05:28","pubTimestamp":1763069313,"startTime":"0","endTime":"0","summary":"Acrivon Therapeutics Q3 net loss narrows to $18.2 mlnOverviewAcrivon Q3 net loss narrows to $18.2 mln from $22.4 mln last yearResearch and development expenses fell due to fewer milestones and focus o","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nL1N3WP194:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACRV","BK4139"],"gpt_icon":0},{"id":"2583512919","title":"Acrivon Therapeutics, Inc Q3 Income From Operations USD -19.687 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2583512919","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583512919?lang=en_us&edition=fundamental","pubTime":"2025-11-14 05:25","pubTimestamp":1763069126,"startTime":"0","endTime":"0","summary":"Nov 13 (Reuters) - Acrivon Therapeutics, Inc Q3 operating expenses USD 19.687 million.:  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))  Source Date/Time = 13-NOV-202521:08:00.11 GMT","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nRSD6Dfmd4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACRV","BK4139"],"gpt_icon":0},{"id":"2581065756","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2581065756","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581065756?lang=en_us&edition=fundamental","pubTime":"2025-11-06 19:00","pubTimestamp":1762426800,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·A-Mark Precs Mtl                                1Q       .60    4:05 PM. ·Achve Life Scncs                                3Q      (.24)   7:30 AM. ·Air Pdts and Chem                                4Q      3.38    6:00 AM. ·Alpha Metall Rsrcs                               3Q      (.52)   7:30 AM. ·Altice USA Inc.                                 3Q      (.06)   7:00 AM","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["APYX","ABCL","ALG","ATHM","ADVM","ALT","AHR","ALLO","APLT","ARLO","ABNB","ASMB","ATUS","AMPH","GOOS","ACHV","AORT","OPTU","APD","AAOI","ACIW","AAON","ASPN","AMR","AMTX","BLZE","ADV","ACRV","ALTG","AVAH","BIRD","AMN","ATYR","ATLC","AFRM","ASTH","AMRK","AMBQ","AEE","AMLX","AURA","CARL","AKAM","AMPX","ABL","ALRM","BIOA","AGO","ARHS","APPN"],"gpt_icon":1},{"id":"2577831670","title":"Acrivon Therapeutics Announces Initial Clinical Data for Novel WEE1/PKMYT1 Inhibitor ACR-2316","url":"https://stock-news.laohu8.com/highlight/detail?id=2577831670","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577831670?lang=en_us&edition=fundamental","pubTime":"2025-10-23 04:17","pubTimestamp":1761164249,"startTime":"0","endTime":"0","summary":"Acrivon Therapeutics Inc. has announced upcoming presentations of preclinical and initial clinical data for its novel candidate ACR-2316 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, taking place October 22-26, 2025, in Boston, MA. The data will highlight the company's proprietary Generative Phosphoproteomics AP3 platform, including the AP3 KaiSR ensemble model, which is used to optimize drug design for specific pathway effects in tumor cells. Preclinical results have demonstrated differentiated and superior pathway effects of ACR-2316 compared to benchmark WEE1 and PKMYT1 inhibitors. Initial clinical data from the ongoing Phase 1 study, including observed clinical activity and a confirmed partial response during dose escalation in AP3-predicted solid tumor types, will be reported later this year. The posters will be available on Acrivon's website following their presentation at the conference.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251022:nNDLyT2vN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IE00B64PRP62.GBP","LU2095319765.USD","LU0314104364.USD","LU2210150020.SGD","IE00BKPKM429.USD","BK4588","IE00B3QW5Z07.USD","BK4112","LU2210149790.SGD","IE00BGHQF748.EUR","ACRV","NDAQ","BK4585"],"gpt_icon":0},{"id":"2572572115","title":"Acrivon Therapeutics Grants Stock Options to New Employee Under 2023 Inducement Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2572572115","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572572115?lang=en_us&edition=fundamental","pubTime":"2025-10-02 04:30","pubTimestamp":1759350614,"startTime":"0","endTime":"0","summary":"Acrivon Therapeutics Inc. has announced the approval of a new equity award for an employee under its 2023 Inducement Plan. The award consists of stock options to purchase 225,000 shares of Acrivon common stock, with an exercise price set at the closing price on the grant date, October 1, 2025. The options vest 25% after one year from the month following the employee's start date, with the remaining options vesting in equal monthly installments over the subsequent three years.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Acrivon Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on October 01, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251001:nNDL9D5gKm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","ACRV","BK4139","IE00BGHQF748.EUR","IE00BKPKM429.USD","LU0314104364.USD","IE00B3QW5Z07.USD","LU2095319765.USD","LU2210150020.SGD","NDAQ","BK4585","LU2210149790.SGD","BK4112","BK4588"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":28,"code":"91000000","status":"200"}]}}